Bionano Genomics Inc
Change company Symbol lookup
Select an option...
BNGO Bionano Genomics Inc
SSNT SilverSun Technologies Inc
MDLZ Mondelez International Inc
FE FirstEnergy Corp
CADE Cadence Bancorp
SCHD Schwab U.S. Dividend Equity ETF™
ARKK ARK Innovation ETF
URANF International Prospect Ventures Ltd
QSR Restaurant Brands International Inc

Health Care : Life Sciences Tools & Services | Small Cap Blend
Company profile

Bionano Genomics, Inc. is a life sciences instrumentation company in the genome analysis space. The Company develops and markets the Saphyr system. The Company’s products include Sequencing for Discovery Research and Cytogenetics. Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response. The Company’s subsidiary, Lineagen, Inc., provides molecular diagnostics services for individuals.

Closing Price
Day's Change
0.05 (0.85%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:



4 providers
January 22, 2021
UPDATE: Bionano Genomics' stock rally result of awareness push in 2019 and 2020 about its genomic technology: analyst

Shares of Bionano Genomics Inc. (BNGO) gained 10.3% in premarket trading on Friday following a week of heavy trading on the stock. The company's stock price has tripled since the start of the year, closing at $8.27 on Jan. 21, compared to $3.08...(MarketWatch)

Bionano Genomics stock price target raised to $14 from $2 at Maxim Group

(END) Dow Jones Newswires January 22, 2021 07:38 ET (12:38 GMT) (MarketWatch)

January 20, 2021
UPDATE: Bionano Genomics prices $200 million underwritten stock offering at a discount of $6 a share

Bionano Genomics Inc. (BNGO) priced a $200 million underwritten stock offering announced late Tuesday ( a discount of $6 a share, selling 33.3...(MarketWatch)

Bionano Genomics prices $200 mln underwritten stock offering at discount of $6 a share

(END) Dow Jones Newswires January 20, 2021 07:51 ET (12:51 GMT) (MarketWatch)

January 19, 2021
Bionano Genomics to sell more shares, stock falls

Bionano Genomics Inc. (BNGO) on Tuesday announced its second share sale in less than a month amid an unexplained spike in its price and volume, sending shares down in after-hours trading. Bionano did not disclose a targeted number of shares nor...(MarketWatch)

January 08, 2021
UPDATE: Bionano Genomics prices offering of 29 million shares at discount of $3.05 a share

Bionano Genomics Inc. (BNGO) said Friday it has priced an underwritten public offering of 29 million shares at $3.05 a share. The stock closed Thursday at $5.00. The genome analysis company has granted the underwriters -- Oppenheimer & Co...(MarketWatch)

Bionano Genomics to offer stock in underwritten deal

(END) Dow Jones Newswires January 08, 2021 07:12 ET (12:12 GMT) (MarketWatch)

Bionano Genomics to offer stock in underwritten deal

(END) Dow Jones Newswires January 08, 2021 07:11 ET (12:11 GMT) (MarketWatch)

January 07, 2021
Bionano Genomics shares fall after plan to sell more stock

Bionano Genomics Inc. (BNGO) plans to sell more shares after a sudden surge in its stock price in recent weeks, and shares dove in after-hours trading Thursday in response. The company revealed Thursday afternoon that it expects to sell more...(MarketWatch)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.